Compare BridgeBio Pharma Inc (BBIO) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard Mega Cap Growth ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Vanguard Mega Cap Growth ETF trades at $91.07. Which is the better fit depends on your goals.
| BBIO | MGK | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $92.06 |
52-Week Low | $47.29 | $70.70 |
Enterprise Value | $18.14B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
